Position of the Transparency Council – Lamprene (clofazimine)

At its meeting on 31 March 2025, the Transparency Council adopted position No. 39/2025 on the legitimacy of issuing approvals for the reimbursement of the drug Lamprene (clofazimine) for the indications: pulmonary mycobacteriosis, multidrug-resistant pulmonary tuberculosis

Publication of the position >>